Posts tagged non-alcoholic steatohepatitis
HCW assumes coverage of DURECT at buy

H.C. Wainwright has assumed coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and $3 price target. The stock was quoted at $1.02 in afternoon trading on Feb. 28.

Read More
Galectin completes patient recruitment in NASH trial

Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX trial. The company expects to report the topline results of the trial in December 2017.

Read More
HCW starts Tobira Therapeutics at buy

H.C. Wainwright has initiated coverage of Tobira Therapeutics (NASDAQ:TBRA) with a “buy” rating and $22 price target. The stock closed at $7.30 on Friday.

Tobira is focused on the development of a sole drug candidate, cenicriviroc (CVC), as a treatment for non-alcoholic steatohepatitis (NASH). NASH is a disease of the liver that can lead to fibrosis, cirrhosis, and ultimately, transplant or hepatocellular carcinoma.

Read More
Can-Fite unveils clinical milestones for 2016

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has announced its anticipated clinical milestones for 2016.

“We are very encouraged by the clinical and preclinical data from each of our drugs to date, which indicate their efficacy across six major indications,” CEO, Dr. Pnina Fishman, said in a statement.

Read More